Cargando…

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1

Detalles Bibliográficos
Autores principales:	Ahmed, T, Borthwick, N, Yang, H, Hancock, G, Yorke, L, Ebrahimsa, U, Rose, A, Black, A, Hayton, E, McMichael, A, Dorrell, L, Hanke, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441714/ http://dx.doi.org/10.1186/1742-4690-9-S2-P259

Ejemplares similares

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
por: Borthwick, NJ, et al.
Publicado: (2012)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
por: Moyo, Nathifa, et al.
Publicado: (2017)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice()
por: Ondondo, Beatrice, et al.
Publicado: (2013)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
por: Hancock, Gemma, et al.
Publicado: (2017)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
por: Ondondo, Beatrice, et al.
Publicado: (2006)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
por: Joachim, Agricola, et al.
Publicado: (2015)

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions
por: Kopycinski, Jakub, et al.
Publicado: (2023)

Novel Nested Peptide Epitopes Recognized by CD4(+) T Cells Induced by HIV-1 Conserved-Region Vaccines
por: Borthwick, Nicola, et al.
Publicado: (2020)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes
por: Ahmed, Tina, et al.
Publicado: (2016)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2017)

Identification of novel HIV-1-derived HLA-E-binding peptides
por: Hannoun, Zara, et al.
Publicado: (2018)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
por: Elias, Sean C, et al.
Publicado: (2014)

Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2023)

Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
por: Létourneau, Sven, et al.
Publicado: (2007)

The HIV-1 protective -35SNP effect in Caucasians is CD8 T cell mediated
por: Corrah, T, et al.
Publicado: (2012)

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Correction: Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
por: Létourneau, Sven, et al.
Publicado: (2011)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

P17-05. Dealing with HIV-1 diversity
por: Rosario, M, et al.
Publicado: (2009)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses
por: Hancock, Gemma, et al.
Publicado: (2015)

Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8(+) T Cell Responses in HIV-1-Infected Individuals
por: Climent, Núria, et al.
Publicado: (2011)

Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses
por: Climent, N, et al.
Publicado: (2012)

The dual role of tetraspanin CD63 in HIV-1 replication
por: Li, Guangyu, et al.
Publicado: (2014)

Priming with a Recombinant Pantothenate Auxotroph of Mycobacterium bovis BCG and Boosting with MVA Elicits HIV-1 Gag Specific CD8(+) T Cells
por: Chapman, Rosamund, et al.
Publicado: (2012)

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

Development of prophylactic vaccines against HIV-1
por: Schiffner, Torben, et al.
Publicado: (2013)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice
por: Jongwe, Tsungai Ivai, et al.
Publicado: (2016)

Novel, in-natural-infection subdominant HIV-1 CD8(+) T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines
por: Borthwick, Nicola, et al.
Publicado: (2017)

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults
por: Mutua, Gaudensia, et al.
Publicado: (2016)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B
por: Rosás-Umbert, Miriam, et al.
Publicado: (2017)

Aptamers that recognize drug-resistant HIV-1 reverse transcriptase
por: Li, Na, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7ikcs4bh15go78ipk3ab0uhhd3